Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3552)
All Articles published online
|
Aug 28, 2012 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Ciccaglione AF, Cellini L, Grossi L, Marzio L. Quadruple therapy with moxifloxacin and bismuth for first-line treatment of |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v18/i32/4386.htm |
| Number | Citing Articles |
| 1 |
Amin Talebi Bezmin Abadi. Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance 2017; 8: 123 doi: 10.1016/j.jgar.2016.11.008
|
| 2 |
Anthony O'Connor, Javier Molina‐Infante, Javier P. Gisbert, Colm O'Morain. Treatment of Helicobacter pylori Infection 2013. Helicobacter 2013; 18(s1): 58 doi: 10.1111/hel.12075
|
| 3 |
Luigina Cellini, Emanuela Di Campli, Soraya Di Bartolomeo, Lucinda Janete Bessa, Marina Baffoni, Mara Di Giulio, D. J. Diekema. New Transport Medium for Cultural Recovery of Helicobacter pylori. Journal of Clinical Microbiology 2014; 52(12): 4325 doi: 10.1128/JCM.02850-14
|
| 4 |
Bilal Ergül, Zeynal Doğan,, Murat Sarikaya, Levent Filik. The Efficacy of Two‐Week Quadruple First‐Line Therapy with Bismuth, Lansoprazole, Amoxicillin, Clarithromycin on Helicobacter pylori Eradication: A Prospective Study. Helicobacter 2013; 18(6): 454 doi: 10.1111/hel.12086
|
| 5 |
Antonio Francesco Ciccaglione, Roberta Tavani, Laurino Grossi, Luigina Cellini, Lamberto Manzoli, Leonardo Marzio. Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third‐Line Treatment of Helicobacter pylori Infection: Two Pilot Studies. Helicobacter 2016; 21(5): 375 doi: 10.1111/hel.12296
|
| 6 |
Yang Yang, Ruizhuo Ouyang, Lina Xu, Ning Guo, Weiwei Li, Kai Feng, Lei Ouyang, Zhuoyuan Yang, Shuang Zhou, Yuqing Miao. Review: Bismuth complexes: synthesis and applications in biomedicine. Journal of Coordination Chemistry 2015; 68(3): 379 doi: 10.1080/00958972.2014.999672
|
| 7 |
Faezeh Kiani, Sara Khademolhosseini, Jasem Mohammadi, Arian Tavasol, Ramtin Hajibeygi, Mobina Fathi, Majid Dousti. Novel Information Regarding the Treatment of Helicobacter pylori Infection:
A Systematic Review and Meta-analysis of Randomized Clinical Trials. Current Reviews in Clinical and Experimental Pharmacology 2024; 19(2): 184 doi: 10.2174/2772432818666230120111237
|
| 8 |
Javier P. Gisbert. Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones. Molecules 2020; 25(21): 5084 doi: 10.3390/molecules25215084
|
| 9 |
Javier P. Gisbert, Marco Romano, Javier Molina-Infante, Alfredo J. Lucendo, Enrique Medina, Inés Modolell, Manuel Rodríguez-Tellez, Blas Gomez, Jesús Barrio, Monica Perona, Juan Ortuño, Inés Ariño, Juan Enrique Domínguez-Muñoz, Ángeles Perez-Aisa, Fernando Bermejo, Jose Luis Domínguez, Pedro Almela, Judith Gomez-Camarero, Judith Millastre, Elisa Martin-Noguerol, Antonietta G. Gravina, Marco Martorano, Agnese Miranda, Alessandro Federico, Miguel Fernandez-Bermejo, Teresa Angueira, Luis Ferrer-Barcelo, Nuria Fernández, Alicia C. Marín, Adrián G. McNicholl. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments. Digestive and Liver Disease 2015; 47(2): 108 doi: 10.1016/j.dld.2014.10.009
|
| 10 |
Meng-Chieh Wu, Yao-Kuang Wang, Chung-Jung Liu, Fang-Jung Yu, Fu-Chen Kuo, Min-Li Liu, Chao-Hung Kuo, Deng-Chyang Wu, Yao-Kang Huang, I-Chen Wu. Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori. Gastroenterology Research and Practice 2017; 2017: 1 doi: 10.1155/2017/5320180
|
| 11 |
Amin Talebi Bezmin Abadi. Therapy ofHelicobacter pylori: Present Medley and Future Prospective. BioMed Research International 2014; 2014: 1 doi: 10.1155/2014/124607
|
| 12 |
Halil Rakici, Remzi Adnan Akdoğan, Recep Bedir, Aysegul Copur, Arif Yilmaz. Comparison of standard triple therapy, sequential therapy and moxifloxacin‐based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates. Journal of Digestive Diseases 2014; 15(9): 508 doi: 10.1111/1751-2980.12171
|
| 13 |
Halil Rakici, Teslime Ayaz, Remzi Adnan Akdogan, Recep Bedir. Comparison of Levofloxacin- and Moxifloxacin-Based Triple Therapies with Standard Treatment in Eradication of Helicobacter Pylori as First-Line Therapy. Digestion 2014; 90(4): 261 doi: 10.1159/000369788
|
| 14 |
J. P. Gisbert, M. Romano, A. G. Gravina, P. Solís‐Muñoz, F. Bermejo, J. Molina‐Infante, M. Castro‐Fernández, J. Ortuño, A. J. Lucendo, M. Herranz, I. Modolell, F. del Castillo, J. Gómez, J. Barrio, B. Velayos, B. Gómez, J. L. Domínguez, A. Miranda, M. Martorano, A. Algaba, M. Pabón, T. Angueira, L. Fernández‐Salazar, A. Federico, A. C. Marín, A. G. McNicholl. Helicobacter pylori second‐line rescue therapy with levofloxacin‐ and bismuth‐containing quadruple therapy, after failure of standard triple or non‐bismuth quadruple treatments. Alimentary Pharmacology & Therapeutics 2015; 41(8): 768 doi: 10.1111/apt.13128
|
| 15 |
Dong Liang, Jing Ma, Bo Wei. Oral absorption and drug interaction kinetics of moxifloxacin in an animal model of weightlessness. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-82044-3
|